semaglutide weight loss program pennsylvania Philadelphia Medical Weight Loss Program |

Semaglutide (GLP-1) and its brand Ozempic are both effective options for weight loss, originally developed to manage type 2 diabetes

A retrospective analysis of 461,382 adults treated with GLP-1 receptor agonists found that nutritional deficiencies were diagnosed in 12.7% of patients within six months and 22.4% within twelve months, with vitamin D deficiency the most common at roughly 13.6% by the one-year mark

Key Legal Developments Rapid Growth of Cases: As of early February 2026 , the consolidated MDL had grown to 3,191 pending actions , reflecting a dramatic expansion of plaintiff participation over the last two years

Alcohol use disorder (AUD) is a brain disorder affecting more than 28 million adults in the United States, according to the AUD is characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences

Oregon Live

Ask your clinician to do a medication review as well, in case your meds need adjusting